男性节育药物的研发进展  

Advance in development of male contraceptives

作　　者：李国停 谢淑武[2] 朱焰[2] 

机构地区：[1]复旦大学,上海200032 [2]上海市计划生育科学研究所生殖药理组,国家卫生和计划生育委员会计划生育药具重点实验室,上海生殖健康药具工程技术研究中心,上海200032

出　　处：《中国新药杂志》2014年第1期55-61,共7页Chinese Journal of New Drugs

基　　金："十二五"国家科技支撑计划(2012BAI31B08);国家自然科学基金(81100463)

摘　　要：男性节育药物主要有激素和非激素两大类。激素类男性节育药主要通过服用外源性的激素抑制精子的发生,包括雄激素、雄激素与孕激素联合应用、雄激素与GnRH类似物联合应用等。非激素类男性节育药种类较多且处于不同的研发阶段。首先是干扰支持细胞功能的Adjudin,Gamendazole,CDB4022;其次为睾丸"溴"结构域特异性蛋白(BRDT)抑制剂JQ1;最后是顶体酶抑制剂KF-950及棉酚,以及视黄酸抑制剂等。本文就近几年男性节育药的研究进展作一综述。Male contraceptives are classified into hormonal and non-hormonal agents. Administration of ex- ogenous hormones to men can suppress spermatogenesis, including regimens of testosterone alone, testosterone-pro- gestin combination, and testosterone-gonadotropin-releasing hormone （GnRH） analog combination. There are sev- eral promising non-hormonal male contraceptives at various stages of research and development, including Adjudin, Gamendazole, and CDB4022 which disrupt the adhesion of spermatids to the Sertoli cells, a small molecule inhibi- tor of Bromodomain testis-specific protein （BRDT）, JQ1, acrosin inhibitors KF-950 and gossypol, and retinoic acid inhibitors. This review focused on their advances in recent years.

关 键 词：男性节育药 激素类 非激素类 

分 类 号：R977.12[医药卫生—药品]